No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Commentary|Podcasts|August 2, 2024
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Listen
0:00 / 0:00
Explore the disease progression of atopic dermatitis and strategies to make a difference in patients' lives.
Advertisement
We recently caught up with Peter Lio, MD, a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, at the
Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at
Advertisement
Related to this article
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
At Fall Clinical 2026, Glynis Ablon, MD, recommends body dysmorphic disorder screening and systematic documentation in aesthetics, plus early combination therapy for multifactorial alopecia.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
Advertisement
Advertisement
Trending on Dermatology Times
1
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
2
Nemolizumab Maintains Deep Skin and Itch Responses Through 3 Years in Atopic Dermatitis
3
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
4
Ixekizumab Plus Tirzepatide Shifts Biomarkers in Psoriasis with Obesity
5